Heart Failure and Qof Quiz Justin Walker October 2010.

Slides:

Advertisements

Similar presentations

Vasodilating Versus First- Generation β-blockers for Cardiovascular Protection Scott Morgan MSIII November 2012.

Advertisements

By Carla, Tona, Raj, Clare, and Masood

Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.

Emergency/Urgent Referral* (3) -Pt acutely unwell with palpitations -Pt with haemodyanically unstable acute onset AF -2 nd /3 rd heart block -Exercise.

ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.

BACK TO BASICS: PHARMACOLOGY CHAD C. CRIPE, MD Department of Anesthesiology & Critical Care Medicine Division of Cardiothoracic Anesthesiology The Children’s.

Diastolic Heart Failure, HFpEF, HFnEF: What are we treating anyway? Charles M. Rasmussen, MD FACC.

Heart Failure Management Focus on Primary Care Practice.

ASCOT TRIAL Abbas Zaidi 20/09/05. Hypertension is one of the most prevalent risk factors for cardiovascular disease, affecting as many as 800 million.

Hypertension – Summary

1 Heart Failure William Chavey, MD, MS Associate Professor Department of Family Medicine University of Michigan.

HEART FAILURE “pump failure” DEFINITION Heart failure is the inability of the heart to supply adequate blood flow and therefore oxygen delivery to.

Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

Heart Failure 2014 Dr Maurice Pye Consultant Cardiologist

HEART FAILURE MANAGEMENT -RAAS BLOCKERS FAZIL BISHARA SR- CARDIOLOGY

Dorset Improving Diagnosis of Heart Failure Implementation of BNP Measuring in General Practice Ist Project Steering Group 13 th Sept 2011.

Diagnosing Heart Failure Sanjay Kumar Lead Consultant Cardiologist Grace Williams Lead Heart Failure Specialist Nurse Croydon Health Services NHS Trust.

Dr. Jon Salisbury Visiting Physician Services A Member of VNA Health Group No Disclosures May 14, :40PM – 2:00PM ©AAHCM.

Management of Chronic Heart Failure SIGN 95

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen.

Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.

Drugs for Hypertension

Update on  -Blockers In the Management of Heart Failure.

Heart Failure Ben Starnes MD FACC Interventional Cardiology

Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.

Indication:  Suspected Heart Failure With abnormal ECG or Intermediate BNP ( ) BNP:  Asymptomatic Murmur  Asymptomatic Cardiomegaly On CXR Direct.

Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.

Massie I-PRESERVE Trial Irbesartan in heart failure with preserved EF Co-PIs: Barry Massie and Peter Carson Executive Committee M. Komajda, R. McKelvie,

L References Application to Clinical Practice The American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) have cooperatively.

 Hypertension : BPDIASTOLIC SYSTOLIC Normal< 130< 85 Mild hypertension Moderate hypertension Severe Hypertension 180.

1 Hypertension Overview. 2 Leading Risks For Death (World Health Organization 2002) Cholesterol Alcohol HYPERTENSION Tobacco use Overweight.

Entresto® (sacubitril & valsartan)

Antihypertensives Dr Thabo Makgabo.

Chronic Heart Failure Clinical case scenarios for primary care Educational Resource Implementing NICE guidance August 2010 NICE clinical guideline 108.

Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.

Heart Failure. Background to Congestive Heart Failure Normal cardiac output needed to adequately perfuse peripheral organs – Provide O 2, nutrients, etc.

Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Thumbs up/Thumbs down – Oct 2002 OPTIMAAL OPTIMAAL: Does the dose make the medicine? Eric J Topol MD Provost and Chief Academic Officer Chairman, Department.

Dr.AZDAKI (cardiologist).   Initial monotherapy is successful in many patients with mild primary hypertension (formerly called "essential" hypertension).

Therapeutics of Hypertension By Prof. Mohammad Saleh Hassan.

Pharmacology of Renin-Angiotensin system

PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.

HEART FAILURE. Excellent Care 1. Diagnosis 2. ACE-I and B blocker 3. Aldosterone antagonist 4. Exercise 5. Statin and aspirin if CVD 6. Digoxin with AF.

Prescribing in cardiovascular disease By Jole Hannan Medicines Optimisation Pharmacist.

Internal Medicine Workshop Series Laos September /October 2009.

1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.

HF diagnosis: audit of NTproBNP uptake and outcomes across Sheffield An update on diagnosis and management of HF Dr Abdallah Al-Mohammad, MD, FRCP(Edin),

Chronic heart failure By Vishal Patel GPVTS1.

Fig ACCF/AHA Guideline for the management of heart failure

Guideline: Chronic Heart Failure

Hypertension JNC VIII Guidelines.

Drugs for Hypertension

Beyond Current Strategies: Focus on Angiotensin Receptors

51st Annual Scientific Session for the LIFE Investigators

UNIT 2: ANTIHYPERTENSIVE DRUGS

Section III: Neurohormonal strategies in heart failure

Step Care Therapy for Hypertension in Diabetic Patients

West Essex Frailty Pathway: Heart Failure

Fig. 2. Evidence-based medication prescriptions

Table of Contents Why Do We Treat Hypertension? Recommendation 5

The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study was a double-blind, randomized, placebo-controlled study.

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Pharmacological Treatment of Hypertension Update 2012

Internal Medicine Workshop Series Laos September /October 2009

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Presentation transcript:

Heart Failure and Qof Quiz Justin Walker October 2010

Old or New?  Refer patients with suspected heart failure and previous MI urgently, to have transthoracic Doppler 2D echocardiography and specialist assessment within 2 weeks.

New!

Old or New?  People with suspected heart failure should initially have a 12 lead ECG and/or BNP to exclude the condition.

Old!  2010 guidelines suggest echo within 2 weeks if previous MI, BNP if not.

True or False?  Which of the following factors can lower BNP? Obesity Obesity Diuretics Diuretics ACE inhibitors ACE inhibitors Tachycardia Tachycardia PE PE Diabetes Diabetes

True or False?  Which of the following factors can lower BNP? ObesityTrue ObesityTrue DiureticsTrue DiureticsTrue ACE inhibitorsTrue ACE inhibitorsTrue TachycardiaFalse TachycardiaFalse PEFalse PEFalse DiabetesFalse DiabetesFalse

True or False?  The normal range for BNP is pg/mol.

False!  The normal range for BNP is <100 pg/ml  Raised pg/ml – Refer within 6 weeks  High >400 pg/ml – Refer within 2 weeks

Beta Blockers  Which of the following are licensed for the treatment of heart failure? Atenolol Atenolol Propanolol Propanolol Bisoprolol Bisoprolol Carvedilol Carvedilol Nebivolol Nebivolol Labetalol Labetalol Sotalol Sotalol

Beta Blockers  Which of the following are licensed for the treatment of heart failure? Bisoprolol Bisoprolol Carvedilol Carvedilol Nebivolol Nebivolol Bisoprolol and carvedilol in any grade of stable heart failure, nebivolol for stable mild to moderate HF.

Angiotensin II Receptor Antagonists  Which of the following are licensed for use in heart failure? Candesartan Candesartan Eprosartan Eprosartan Irbesartan Irbesartan Losartan Losartan Valsartan Valsartan

Angiotensin II Receptor Antagonists  Which of the following are licensed for use in heart failure? Candesartan Candesartan Losartan Losartan Valsartan Valsartan

Qof Rationale  Heart failure represents the only major cardiovascular disease with increasing prevalence.  Dramatic impairment of quality of life  Poor prognosis  Costly to treat.  Which is the most expensive for the NHS, myocardial infarction, heart failure or stroke?

Ranking  Stroke  Heart failure  Myocardial infarction

Qof Indicators  Register of patients with heart failure  Percentage of patients with HF confirmed by echo or specialist assessment.  Percentage of pts with HF due to LVD on an ACE-i or ARB who can tolerate therapy with no contraindication.  Percentage of pts with HF due to LVD on an ACE-i or ARB additionally treated with a licensed beta-blocker or with recorded intolerance or contraindication.  Points available 4,6,9,10

Qof Indicators  Register of patients with heart failure 4 points  Percentage of patients with HF confirmed by echo or specialist assessment. 6 points  Percentage of pts with HF due to LVD on an ACE-i or ARB who can tolerate therapy with no contraindication. 10 points  Percentage of pts with HF due to LVD on an ACE-i or ARB additionally treated with a licensed beta-blocker or with recorded intolerance or contraindication. 9 points